2007'09.08.Sat
Webcams.Travel Goes Chinese
September 06, 2007
VADUZ, Switzerland, Sept. 6 /Xinhua-PRNewswire/ -- Do
you want to visit world famous places like the Golden Gate
Bridge in San Francisco, the spectacular Matterhorn in
Switzerland and nice beaches in the Caribbean? Now you can
do that without any effort at all. Just visit
webcams.travel where users from around the world have
access to more than 2,500 travel webcams showing the most
beautiful holiday destinations on earth.
http://www.Webcams.travel is now available in simplified
Chinese and 7 other languages.
webcams.travel is a second-generation webcam portal
based on the map solutions of Google Maps and Google Earth.
Users can rate webcams, place comments on any of them or add
the most interesting to their personal favorites list. At
present approximately 2,500 of the most beautiful and
fantastic webcams from all over the world are available.
Webcam owners can now add their webcam to
webcams.travel for free and place it at the right location
on the map. It only takes a few minutes. That gives the
owners of a webcam a much broader exposure of their webcam
pictures to users worldwide.
On today's Internet, webcams are a very powerful online
marketing instrument as more and more holiday destinations,
mountain railways and even hotels are installing webcams,
all with the intent of having users find and visit them.
Webcams.travel is available in English, German, Dutch,
Spanish, Portuguese, French, Japanese and now also in
simplified Chinese: http://www.webcams.travel. More
languages will follow.
Webcams.travel belongs to Topin.travel, a portal for
holidays and leisure focused on the German speaking part of
Europe. On Topin.travel users find more than 6,000 ideas for
trips, tours, excursions and holidays.
http://www.webcams.travel is operated by OPAG Online
Promotion AG.
For more information, please contact:
Jorg Eugster, CEO
OPAG Online Promotion AG
Austrasse 37
FL-9490 Vaduz
Tel: +423-230-06-50
Email: joerg.eugster@webcams.travel
Website: http://www.webcams.travel
PR
2007'09.08.Sat
Lulu Enterprises Files Suit Against Hulu for Trademark Infringement
September 06, 2007
RALEIGH, N.C., Sept. 6 /Xinhua-PRNewswire/ -- Lulu
Enterprises ( http://www.lulu.com ) announced today that it
has filed suit against N-F Newsite LLC ("Hulu")
for trademark infringement, unfair and deceptive trade
practices and for federal cyberpiracy.
In the complaint, filed in US District Court in
Raleigh, NC, Lulu alleges that Hulu ( http://www.hulu.com
), as a result of their recent name and Internet domain
announcements, have intentionally attempted to create
confusion in the marketplace. Hulu, in name, as a mark and
in their business as a digital content distribution
platform, represents a definitive encroachment.
In addition to the conflict in business for digital
video, Hulu's trademark filing, filed on August 22, 2007,
identifies various products and services, many of which are
related to, and even identical to, the services that Lulu
provides under its Lulu marks.
"We have spent more than five years and tens of
millions of dollars in investment successfully building
the Lulu brand and website into a place for millions of
creators and consumers to publish, buy, sell and manage
digital content," said Lulu CEO Bob Young. "It is
clear we are required to move quickly to protect our
intellectual property and defend ourselves against this
infringement before it significantly damages our
business."
Lulu ( http://www.lulu.com and http://www.lulu.tv ), a
privately held company, was launched in 2002 and allows
creators to publish both contextual-based and multimedia
content in a variety of applications. Lulu has almost 1.2
million registered users and receives more than three
million unique visitors per month between its global sites.
Lulu users currently publish more than four thousand new
pieces of content -- books, video, calendars, music -- each
week and is growing rapidly with almost 15,000 new
registrations per week. As a marketplace, Lulu has paid out
millions of dollars in creator earnings.
For more information, please contact:
Gail Jordan
Lulu Enterprises
Tel: +1-919-723-8632
Email: gjordan@lulu.com
2007'09.08.Sat
Landor Associates and Economist Conferences Make Bold Move: Fourth China Branding Roundtable Goes to Beijing
September 06, 2007
WPP Chief Executive, Sir Martin Sorrell, to Deliver Keynote
Address
BEIJING, Sept. 6 /Xinhua-PRNewswire/ -- Landor
Associates is proud to announce its continued role as
founding sponsor of the Economist Conferences' Fourth China
Branding Roundtable, "Winning Moves for a Changing
Game," to be held September 18th and 19th, 2007. Held
in Shanghai for the last three years, this year's event
moves to Beijing, the bustling mecca of business in the
East and host city to the 2008 Olympics.
Sir Martin Sorrell, Chief Executive of WPP, will
deliver the keynote address on the first day. He will
discuss the future of marketing during a session entitled
"Marketing Today and Tomorrow: A View From the WPP
Observatory."
"I've watched and admired Landor's efforts to
bring timely, topical issues to the forefront through their
global relationship with the Economist Conferences
Group," said Sir Martin. "As clients across the
WPP network are focused on this ever-changing market, our
goal is to provide them with smart, well-rounded solutions
to their most burning issues. I look forward to sharing
with the audience our take on the current business climate,
how this impacts an increasingly global marketplace and how
integrated communications can secure a successful brand
life-cycle."
Based on the success of his book "BrandSimple: How
the Best Brands Keep It Simple and Succeed," Allen
Adamson, Managing Director of the New York office of
Landor, will close the first day of the event in a session
entitled, "Brand Simple: The Key to Success."
Allen will use case studies from the upcoming Chinese
edition of the book to illustrate how brands can apply
clear and concise branding practices to ensure success in
the fast-moving Chinese market.
"I look forward to presenting at the upcoming
China Branding Roundtable in Beijing," said Adamson.
"All eyes have been on China for the last two years,
and increasingly so with the recent business news and the
upcoming Olympics. My goal is to communicate that although
China is still considered a developing market by the
outside world, there are key tenets to branding that will
enable the success of brands, whether local or
international."
As in past years, this event has drawn representatives
from top-tier local and multi-national brands to share
their insights on successful marketing techniques.
Confirmed speakers include Joy Lee, Marketing Director for
DHL Express China; Diane Ho, Marketing and Communications
Director, Greater China for Jones Lang LaSalle Shanghai;
Ian Chapman-Banks, Vice President of Marketing for Motorola
Asia-Pacific Mobile Devices; Dan Wong, Vice President, Sales
and Channel Management Multimedia for China Area, Nokia; and
Sam Su, President, China Division for YUM! Brands.
Event sessions will range from the changing face of the
Chinese consumer, to the impact of marketing deregulation,
to creating competitive advantage through
precision-marketing. The Regent Hotel in Beijing will be
the site of the one-and-a-half day event. For more
information, please visit http://www.landor.com/economist
or http://www.economistconferences.com.
About Landor Associates:
Landor Associates is one of the world's leading
strategic brand and design consultancies. Founded by
Walter Landor in 1941, Landor pioneered many of the
research, design and consulting methods that are now
standard in the branding industry. Partnering with
clients, Landor drives business transformation and
performance by creating brands that are more innovative,
progressive and dynamic than their competitors.
Landor's holistic approach to branding is a balance of
rigorous, business-driven thinking and exceptional
creativity. Its work spans the full breadth of branding
services, including brand research and valuation, brand
positioning and architecture, naming and writing, corporate
identity and consumer packaging design, branded experience,
brand equity management, brand engagement and digital
branding.
With 23 offices in 17 countries, Landor's current and
past clients include some of the world's most powerful
brands, including BP, Cathay Pacific, Citi, Danone, Delta,
Diageo, Emaar Properties, FedEx, Frito-Lay, the City of
Hong Kong, HSBC, LG Group, Marriott Hotels & Resorts,
Microsoft, Procter & Gamble and PepsiCo.
Landor is part of WPP, one of the world's largest
global communications services companies.
For more information, please visit
http://www.landor.com.
For more information, please contact:
Mindy Romero, Manager of Public Relations
Landor Associates
Phone: +1-212-614-5261
Email: mindy_romero@landor.com
Liz Biebl, Account Executive
Cohn & Wolfe
Phone: +1-415-365-8544
Email: liz_biebl@sfo.cohnwolfe.com
2007'09.08.Sat
Supermicro Unveils Quad-Core Quad-Processor Servers
September 06, 2007
Energy-efficient 1U, 2U & 4U SuperServers deliver
breakthrough performance-per-watt(1) with new Quad-Core
Intel(R) Xeon(R) Processor 7300 Series
SAN JOSE, Calif., Sept. 6 /Xinhua-PRNewswire/ --
Super Micro Computer, Inc. (Nasdaq: SMCI), a leader in
application optimized, high performance server solutions,
today announced availability of the industry's first line
of quad-core, quad-processor servers. Supermicro's new
8015C-T, 8025C-3R and 8045C-3R SuperServers feature a
larger memory footprint, improved energy efficiency and
more form factors and CPU SKUs to choose from for better
application optimization compared to previous generation
quad-processor servers based on Intel(R) Xeon processors.
"With Supermicro's industry-leading
high-efficiency Super SSI (Server System Infrastructure)
architectural advances and CPU innovations around power
consumption and memory capacity, we are able to deliver
exceptional value to customers looking for consolidation
and virtualization," asserts Charles Liang, president
and CEO of Supermicro. "Our 1U, 2U and 4U
SuperServers based on the new Intel 7300 (Clarksboro)
chipset provide compelling solutions for the dense rack
segment, especially when equipped with Intel's new
mainstream 80-watt or low-voltage 50-watt quad-core
processors."
"The Intel(R) Core Microarchitecture combined with
Intel's quad core technology are again delivering record new
levels of industry performance and energy efficiency, this
time for four processor systems. It's exciting to see
Supermicro aggressively taking advantage of the new
Quad-Core Intel Xeon processor 7300 Series across such a
broad new product line," said Kirk Skaugen, vice
president, Digital Enterprise Group, Intel. "Intel has
designed the new Quad-Core Intel Xeon processor 7300 Series
to enhance virtualization and ease server consolidation,
deliver leading performance, and provide enterprise-level
reliability."
"The Supermicro new quad-processor servers provide
more virtual machine headroom with double the processing
cores and double the memory capacity of previous
generation," said David Driggers, CTO of Verari
Systems. "With the new 50-watt processor options, we
can continue to enable energy efficient ultra-dense
deployments with large memory footprints and scalability to
empower our customers with greater productivity."
Based on Supermicro's new X7QCE and X7QC3 serverboards,
the 8015C-T, 8025C-3R and 8045C-3R SuperServers all support
up to 192GB of fully buffered DDR2 667 or 533 MHz memory
via 24 DIMM slots (when equipped with 8G modules). Great
for virtualization, this expanded memory capacity boosts
performance for a wide range of applications.
With 90% power supply efficiency and optimal cooling
designs, these energy-efficient servers deliver
breakthrough performance-per-watt(1). Ready for
next-generation 45nm processors, the performance boosting
features of these systems also include four dedicated
high-speed interconnects, quad-core processors with Intel
Core microarchitecture, and 64 MB snoop filter.
Supermicro offers new quad-processor SuperServers in
1U, 2U and 4U form factors for customers to choose from
that support the full range of Xeon 7300 (Caneland)
processor SKUs. With performance optimized 130-watt, rack
and blade optimized 80-watt, and high-density rack and
blade optimized 50-watt SKUs, customers now have more
choices than ever before to select the server that is best
for their applications.
Supermicro Server Building Block Solutions(R) offer
exceptional flexibility and outstanding feature advantages.
For more information on Supermicro's comprehensive line of
server solutions, please visit http://www.supermicro.com .
About Super Micro Computer, Inc.
Established in 1993, Supermicro emphasizes superior
product design and uncompromising quality control to
produce industry-leading serverboards, chassis and server
systems. These mission-critical Server Building Block
Solutions provide benefits across many environments,
including data center deployment, high-performance
computing, high-end workstations, storage networks and
standalone server installations. For more information on
Supermicro's complete line of advanced motherboards,
SuperServers, and optimized chassis, visit
http://www.Supermicro.com , email Marketing@Supermicro.com
or call the San Jose, CA headquarters at
+1-408-503-8000.
SMCI-F
Supermicro and Server Building Block Solutions are
registered trademarks of Super Micro Computer, Inc. Other
names and brands may be claimed as the property of others.
(1) Performance claim based on internal comparisons to
previous generation quad-processor SuperServers optimized
for Intel Xeon processors.
For more information, please contact:
Super Micro Computer, Inc.
Tel: +1-408-503-8000
Email: Marketing@Supermicro.com
2007'09.08.Sat
IntexyS Names CFO and VP Engineering
September 06, 2007
Management Team Expands as New Optical Link Products Debut
TOULOUSE, France, Sept. 6 /Xinhua-PRNewswire/ --
IntexyS Photonics SA, a leader of integrated optical
modules for telecommunications, data communications,
defense and avionics, announced Kevin Taylor as chief
financial officer and Jiashu Chen as vice president of
engineering with both appointments effective in third
quarter. The executives strengthen the French company's
growing management team as new products are scheduled to
debut at ECOC 2007. In Q2, IntexyS had named Terry Thomas
as VP of sales and marketing to drive commercial growth of
high bandwidth optical interconnects.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20070905/AQW066LOGO )
Kevin Taylor joined IntexyS in early September, and
leads the company's finance and administration. He reports
directly to CEO and co-founder Jean-Charles Garcia, and
operates from the Toulouse headquarters.
Prior to joining IntexyS, Mr. Taylor served as CFO for
15 years with companies including Dane-Elec Memory, an
assembler and distributor of DRAM and Flash memory modules;
Pertec, a designer and manufacturer of data storage systems;
and Lectra Systemes, a CAD/CAM systems manufacturer. In
addition, he has nine years of international audit
experience with two Big Four accountancy and professional
service firms, Price Waterhouse in Paris and Arthur Young
& Co. in England.
As VP of Engineering, Jiashu Chen joined IntexyS in
July, responsible for design and development of
optoelectronic modules and subassemblies. Dr. Chen is based
at the IntexyS' office in Sunnyvale, California directly
reporting to CEO Garcia.
Dr. Chen previously held engineering and technical
manager positions with Finisar Corporation, Agere Systems,
and Lucent Technologies. He brings over 20 years of
experience in research and development for hardware and
software solutions, including optoelectronics, embedded
system architecture, and large scale telecommunications
media servers.
"We are excited to have industry experts such as
Kevin, Jiashu and Terry to develop the financial, technical
and commercial strategies to bring our innovative,
'system-in-a-package' products to market," said CEO
Garcia.
About IntexyS
IntexyS Photonics SA designs, manufactures and markets
highly integrated optical-electronic modules for high speed
applications based on its well patented and industrial
proven flip chip hybridization technology. The company
provides multi-standard compliant transmitter and receiver
solutions for serial and parallel optical interconnects.
Headquartered in Toulouse, France, IntexyS Photonics has a
joint R&D laboratory with the CEA/LETI in Grenoble,
France and a U.S. commercial and engineering office in
Sunnyvale, Calif.
For more information, please contact:
Terry Thomas
IntexyS Photonics SA
Tel: +1-408-501-8851
Cell: +1-408-646-7770
Email: tthomas@intexysphotonics.com
2007'09.08.Sat
Emporis Completes Multi-Million Euro Financing Round to Drive Growth
September 06, 2007
DARMSTADT, Germany, Sept. 6 /Xinhua-PRNewswire/ --
Emporis has completed a multi-million Euro financing for
future growth. The company manages and markets building
data in more than 50,000 cities worldwide. The VC Neuhaus
Partners has invested together with KfW Bankengruppe in
this innovative technology business. The specific size of
the deal was not disclosed.
Emporis (http://www.emporis.com ) plans to use this
investment to accelerate growth and drive
internationalization. The Darmstadt company wants to offer
its services in multiple languages as well as make building
data universally accessible and useful. Stephan R. Boehm,
Managing Director at Emporis: "With this data,
companies in the construction and real estate sectors can
analyze their markets and find respective projects and
partners. Emporis manages data regarding the complete life
cycle of a structure: from the concept phase through
demolition. At this juncture our product Emporis Research
comes in."
"The job of Emporis is to organize a complex
puzzle," explains Michael Wutzke, Managing Director at
Emporis. He adds, "Every piece of information expands
the picture we have about the building market. Emporis
merges established business models with "Web 2.0"
services and stores data so that it is semantically
relevant. We generate completely new knowledge from simple
information."
About Emporis:
Emporis is a manager and provider of information on
buildings and other structures on a global basis. Emporis
is leading in the collection of information regarding
high-rise buildings. Internet: http://www.emporis.com
About Neuhaus Partners:
Neuhaus Partners, based in Hamburg is one of Germany's
leading independent venture capital groups. At present,
Neuhaus Partners is in the fundraising process for a new
EUR 100 million technology fund. Internet:
http://www.NeuhausPartners.com .
About KfW:
KfW Bankengruppe provides stimulus for the economy,
society and ecology in Germany, Europe and throughout the
world. With a balance-sheet total of EUR 360 billion it is
one of the large banks in Germany. Internet:
http://www.kfw.de .
Further information:
Full press release: http://press.emporis.com
Emporis company information:
http://corporate.emporis.com
Free building information: http://www.emporis.com
Emporis GmbH
Stephan R. Boehm
Phone: +49-6151-50017-0
Email: press@emporis.com
Neuhaus Partners GmbH
Thomas Golinski
Phone: +49-40-355282-0
Email: golinski@NeuhausPartners.com
2007'09.08.Sat
Weil Gotshal to Open Hong Kong Office; Senior New York Partner Akiko Mikumo to Head Office and become Managing Partner for Asia
September 06, 2007
NEW YORK, Sept. 6 /Xinhua-PRNewswire/ -- Leading global
law firm Weil, Gotshal & Manges announced today its
plans to open an office in Hong Kong in October 2007. The
Hong Kong office will provide firm clients with
transactional counseling throughout Asia, broadening Weil
Gotshal's presence in Asia from its substantial office in
Shanghai. The firm is also in the process of applying for
a license to open an office in Beijing in the near future.
Weil Gotshal also announced its initial strategy to
staff the new Hong Kong operation with deeply experienced
transactional attorneys from both the firm's New York
headquarters and from Shanghai.
Akiko Mikumo, a senior corporate partner from the New
York office and a member of the firm's Management
Committee, will become Managing Partner for Asia and the
head of the Hong Kong office. Ms. Mikumo has a diverse
corporate and securities law practice, with a focus on
mergers & acquisitions for corporate and private equity
clients. She has been repeatedly recognized as a leading
practitioner in her field and was named "Dealmaker of
the Year" by The American Lawyer in 2004. Ms. Mikumo
previously headed the US practice in the firm's London
office from 1998 to 2002.
In addition to Ms. Mikumo, two additional partners will
be relocating to the Hong Kong office: Peter Feist, a
corporate partner from the New York office who focuses on
private equity and mergers & acquisitions, and David
Meredith, a corporate partner from the Shanghai office,
specializing in capital markets. Several of the firm's
highly qualified associates, initially Lindsay Germano and
Roy Wiesner, will also relocate to the Hong Kong office.
About the announcement, Weil Gotshal Chairman Stephen
J. Dannhauser said, "We are delighted to announce the
opening of our Hong Kong office. There are considerable
business opportunities in Asia and these opportunities
continue to create a need for the client-driven,
commercially-minded attorneys that are the hallmark of our
firm. Coupled with our established presence in Shanghai,
our new Hong Kong office evidences our continued commitment
to the region. In line with that commitment, we are sending
some of our best partners and associates to lead this
effort." Continued Dannhauser, "Hong Kong will
provide the platform for Weil Gotshal's expansion into
other Asian markets, including India and Japan, and with
our offices strategically located in Asia, we will have an
exceptional platform to deliver the incisive, best-in-class
legal advice and service clients are asking for throughout
the region."
Ms. Mikumo stated, "I am delighted to have the
opportunity to lead the firm's expansion in Asia. We will
have an extremely talented team in Hong Kong made up of
lawyers who are excited about our opportunities in Asia,
are determined to expand our presence there and will bring
sophisticated, commercially-oriented transactional skills
that will serve our clients well throughout Asia. We are
confident that the office will be a tremendous success.
Under the leadership of Steve Xiang, we already have a
hugely successful office in Shanghai, and we believe that
Weil Gotshal will rapidly expand from that base to become
one of the premier firms in the region."
Steve Xiang, head of the firm's Shanghai office, said,
"Akiko is an outstanding attorney and wonderful
leader, and she is bringing with her a superb team. Peter
Feist is one of the rising stars of our corporate
department in New York and David Meredith has already
established a presence in Hong Kong for capital markets. We
look forward to this broader Asian platform and the
opportunity to build on our local experience and
contacts."
The new Hong Kong office is to be located in Gloucester
Tower in The Landmark complex, located in the Central
financial district of Hong Kong.
About Weil, Gotshal & Manges
Weil, Gotshal & Manges LLP is an international law
firm of 1,200 lawyers, including approximately 300
partners. Weil Gotshal is headquartered in New York, with
offices in Austin, Boston, Budapest, Dallas, Frankfurt,
Houston, London, Miami, Munich, Paris, Prague, Providence,
Shanghai, Silicon Valley, Warsaw, Washington DC and
Wilmington, and opening in Hong Kong in October 2007.
For more information, please contact:
Mike Ford
Weil, Gotshal & Manges
Phone: +1-212-833-3999
Email: mike.ford@weil.com
2007'09.08.Sat
Drive the Future With Fisker Automotive, A New Green American Premium Car Company
September 05, 2007
IRVINE, Calif., Sept. 5 /Xinhua-PRNewswire/ -- Quantum
Technologies and Fisker Coachbuild, LLC announce the launch
of a joint venture in Fisker Automotive, Inc. -- a green
American premium car company. Fisker Automotive will offer
a range of environmentally friendly premium cars -- with the
first production car to make its Worldwide North American
debut at the 2008 Detroit Auto Show in January. Initial
production is anticipated to be 15,000 vehicles annually
with pricing to start under $100,000.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20070905/LAW009LOGO )
Design and technology development are already underway
for the first production car. All models will feature
cutting-edge plug-in hybrid technology penned as Quantum
Drive, developed by Quantum Technologies exclusively for
Fisker Automotive. This all-new plug-in Quantum Drive
chassis layout will allow Fisker to design innovative
luxury cars with uncompromised proportions.
The Fisker name has attracted and attained worldwide
brand recognition, thanks to years of first-class
automotive designs. Over his 18 years in the car design
business, Henrik Fisker has left his thumbprint on some of
the most highly regarded automobiles. His creations range
from the BMW Z8, Aston Martin DB9 & V8 Vantage to his
most recent creations -- the Tramonto and Latigo CS,
designed under the Fisker Coachbuild nameplate. Fisker
Automotive will retain the orange and blue logo originated
at Fisker Coachbuild.
"The troubled environment is captivating the
attention of the world. Developing a premium luxury green
car which also delivers attractive design can make a
difference. We are extremely excited to join our
automotive design expertise with the plug-in hybrid
technology of Quantum in Quantum Drive. This breakthrough
chassis development will allow us to deliver a design with
dramatic proportions -- one which will carry the Fisker
badge," expressed Henrik Fisker, CEO of Fisker
Automotive, Inc. "We want people to drive beautiful
fast cars that make environmental sense -- cars that are
eco-chic and will have less of an impact on global
warming."
Quantum Technologies has a long history of advancing
technology. Benefits in developing an entirely new,
from-the-ground-up design for a plug-in hybrid vehicle
include optimized fuel efficiency and performance,
unchanged gas station infrastructure, home based battery
recharging with any 110-volt outlet at a fraction of the
cost. A cleaner and a quieter car for local travel ... all
with the most advanced comforts that are anticipated with a
luxury car.
"Our goal here is to deliver the advancement that
Quantum Technologies has made in the area of plug-in hybrid
technology. By combining our efforts with the renowned
design talent of Henrik Fisker, we can produce a car that
makes a difference to the environment -- without
sacrificing the luxury that accompanies the finest
automobiles," stated Alan Niedzwiecki, CEO Quantum
Technologies.
Fisker Automotive is a privately owned car company,
operated by executive management teams of Fisker
Coachbuild, LLC and Quantum Technologies with Henrik Fisker
as the CEO of Fisker Automotive. Fisker Coachbuild, LLC will
be the exclusive design house for Fisker Automotive through
the entire range of product development.
About Quantum Technologies:
Quantum is a publicly traded, world leader and OEM
supplier of state-of-the-art clean propulsion technologies,
fuel and energy storage technologies and services including
propulsion systems for hydrogen fuel cell vehicles,
hydrogen internal combustion engine vehicles, compressed
natural gas vehicles, liquid petroleum vehicles, hybrid
electric vehicles and plug-in hybrids based on advanced
electronic control systems and Lithium Ion batteries
developed by Quantum's strategic alliance partner Advanced
Lithium Power Ltd. Quantum also provides engineering
services including vehicle development and homologation and
second stage vehicle manufacturing through its subsidiary
Tecstar.
About Fisker Coachbuild, LLC:
Fisker Coachbuild, LLC is a privately owned company
that has brought a new vision to the world of exotic,
high-end performance sports cars. Their distinctively
designed and expertly engineered automobiles are hand
crafted using only the best quality materials and infused
with cutting-edge safety technology. Fisker Coachbuild
offers elegant and timeless sports cars of limited
production providing the ultimate in exclusivity. The
Fisker line is currently comprised of the Tramonto and
Latigo CS. Creative design services are also carried out
for further brand recognition within Fisker Coachbuild
through merchandising. Designed by Fisker Coachbuild has
also made its mark with the Artega GT design recently
launched at the Geneva Auto Show in 2007. Now the future
strategy will be to focus solely on the design of the
environmental friendly premium cars for Fisker Automotive,
Inc.
For more information, please contact:
Fisker Automotive
Tel: +1-714-888-4255
Fax: +1-714-888-4256
Email: info@fiskerautomotive.com
2007'09.08.Sat
Visteon Progresses Restructuring Through Sale of Indian Powertrain Business
September 05, 2007
CHENNAI, India, Sept. 5 /Xinhua-PRNewswire/ -- Visteon
Corporation (NYSE: VC) announces that it has completed the
sale of Visteon Powertrain Control Systems India (VPCSI) in
Chennai to Adyar River Ltd. This transaction is another
restructuring action the company has achieved to improve
its business.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20001201/DEF008LOGO )
The agreement covers the VPCSI operation in Chennai
which manufactures starters and alternators for global car
makers. The transaction supports the company's strategy to
invest proceeds from the sale of non-core assets in its
market-leading businesses. Employees in the operation will
continue to be employed as part of the transaction. Terms
of the agreement were not disclosed.
"This is another accomplishment in the process of
restructuring our business to focus on our key products and
core technologies," said Donald J. Stebbins, Visteon
president and chief operating officer. "With this
sale, our restructuring program is now more than 50 percent
complete, and this gives us even more flexibility to improve
and grow our business."
For more than seven years, Visteon, a leading supplier
of automotive climate control systems, interiors and
electronics, has had a significant presence in India where
it continues to expand and grow. Today the Visteon India
footprint includes four manufacturing plants and two
technical centers, employing more than 2,000 people. India
is an important part of Visteon's expansion in Asia, the
fastest growing automotive market in the world. Visteon has
55 facilities and 38 manufacturing plants in Asia, which the
company expects to become its largest region by 2009,
generating nearly 50 percent of its revenue.
Visteon Corporation is a leading global automotive
supplier that designs, engineers and manufactures
innovative climate, interior, electronic and lighting
products for vehicle manufacturers, and also provides a
range of products and services to aftermarket customers.
With corporate offices in Van Buren Township, Mich. (U.S.);
Shanghai, China; and Kerpen, Germany; the company has
facilities in 26 countries and employs approximately 43,000
people.
Adyar River Limited is a joint venture between Argyle
Street Management Limited and Leticia Investments Corp.
Founded in 2002, the principal business of Argyle Street
Management Limited (ASM) is management of funds investing
in special situations in Asia. Argyle manages approximately
US$800 million of assets including equity and debt
instruments as well as real estate investments under ASM,
Asia Recovery Fund (ARF), ASM Hudson River Fund (HRF),
certain property fund and discretionary accounts. Argyle's
funds will be investing in Adyar through ARF and HRF.
Leticia Investments Corp. has been actively investing and
building businesses in India for more than 15 years in both
the manufacturing and services sectors.
NOTE TO EDITORS:
Visteon news releases, photographs and product
specification details are available at
http://www.visteon.com
For more information, please contact:
Media
Alison Wright
Director Communications Asia
India mobile: +91-994-068-2032
Tel: +86-21-5208-1100 ext 3047 (China)
Mobile: +86-1376-172-0228 (China)
Email: awright@visteon.com
Jim Fisher
Director Corporate Communications
Tel: +1-734-710-5557
Mobile: +1-734-417-6184
Email: jfishe89@visteon.com
Investors
Derek Fiebig
Tel: +1-734-710-5800
Email: dfiebig@visteon.com
2007'09.08.Sat
Leading Wireless Companies Demonstrate Support For Ultra Mobile Broadband at WIRELESS CHINA INDUSTRY SUMMIT 2007
September 05, 2007
BEIJING, Sept. 5 /Xinhua-PRNewswire/ -- WIRELESS
INDUSTRY SUMMIT 2007 -- The CDMA Development Group (CDG)
today announced a lineup of wireless industry leaders who
support Ultra Mobile Broadband(TM) (UMB(TM)) technology.
Hitachi, Huawei, Motorola, Qualcomm and ZTE will join the
CDG at the Wireless China Industry Summit 2007 to express
their support for UMB to collectively pursue OFDMA-based
technology developments and capitalize on the growing
adoption of high-bandwidth mobile broadband services.
Executives of these companies will participate in a panel
discussion entitled Ultra Mobile Broadband (UMB):
High-Performance Mobile OFDMA Solution, taking place at the
Wireless China Industry Summit 2007, on Wednesday, September
5, from 16:00 - 17:00, Ballroom C on Level 2 in The Landmark
Hotel & Towers, Beijing, China. For information on how
to register, visit http://www.wirelesschina-summit.com .
"The wireless community is beginning to recognize
that UMB will play an important role in setting the
performance bar for OFDMA-based communication services and
will be a leading-edge mobile broadband solution for those
service providers who have access to large amounts of clear
spectrum," said Perry LaForge, executive director of
the CDG. "We look forward to sponsoring some of the
wireless industry's most prominent infrastructure and
technology providers to present UMB's key performance and
business characteristics in Beijing."
UMB is a highly optimized mobile broadband OFDMA
solution designed from the ground up to deliver high-speed
broadband data and VoIP services under highly mobile
conditions. The advanced features, together with a
scalable IP architecture, enable UMB to support a large
selection of IP-based, concurrent and converged services
that require low latency and improved spectral efficiency.
The CDG panel discussion, Ultra Mobile Broadband (UMB):
High-Performance Mobile OFDMA Solution, will feature
individual executive presentations on the business,
technical and deployment advantages of UMB technology,
followed by an interactive question-and-answer session
featuring all participating executives. To learn more
about this seminar please visit
http://www.cdg.org/news/events/070905_ChinaSummit/Beijing%20UMB%20Panel%20Flyer_05SEP2007%20v3.pdf
. To register for the event please visit
http://www.wirelesschina-summit.com .
About CDG
The CDG is a trade association formed to foster the
worldwide development, implementation and use of advanced
wireless technologies. The more than 130 member companies
of the CDG include many of the world's largest wireless
carriers and equipment manufacturers. For more information
about the CDG, contact the CDG News Bureau at
+1-714-540-1030, or visit the CDG Web site at
http://www.cdg.org .
Note to editors
CDMA2000 is a registered trademark of the
Telecommunications Industry Association (TIA-USA). Ultra
Mobile Broadband and UMB are trademarks of the CDG. All
other trademarks are the property of their respective
owners.
Please contact the CDG News Bureau to obtain a
high-resolution file of the UMB logo.
For more information, please contact:
Ricca Silverio
CDG News Bureau
Tel: +1-714-540-1030
Email: cdg@bockpr.com
2007'09.08.Sat
Joint International Health Partners Statement on Behalf of the GAVI Alliance, Global Fund to Fight AIDS, Tuberculosis and Malaria, Joint United Nations Programme on HIV/AIDS (UNAIDS), UNICEF, United Nations Population Fund, World Bank and the World Health Organization
September 05, 2007
LONDON, Sept. 5 /Xinhua-PRNewswire/ --
We, as international health partners committed to
improving health and development outcomes in the world,
welcome and fully support the International Health
Partnership's mission to strengthen health systems, and we
congratulate those involved for setting it in motion.
Despite advances over recent years -- for example, in
expanding vaccination coverage and access to antiretroviral
therapy -- progress towards achieving the key health targets
in the Millennium Development Goals (MDGs) is too slow,
costs lives and must improve. One woman dies in childbirth
each minute. Every day, about 28,000 children under five
die from largely preventable causes, including malaria,
more than 10,000 people are infected with HIV and 22,000
people become sick with tuberculosis.
This is neither fair nor tolerable. Rates of death and
illness must be reduced, health inequalities resolved and
access to basic health services vastly increased.
Urgent action is needed if we are to get back on track
to reach these goals. This process must be country-led and
outcome-driven, based on priorities set out in comprehensive
national health plans. It will require increased emphasis
on collaboration, team-work and effective coordination.
The renewed political interest in strengthening health
systems gives us the important opportunity we need to
redouble our efforts to meet the challenge of the MDGs
head-on. Strengthening health systems means addressing key
constraints related to health worker staffing,
infrastructure, health commodities, logistics, tracking
progress and effective financing.
We will be coordinated and accountable in this work and
take every opportunity to capture knowledge and lessons
learned in improving health programmes. Jointly, we will
provide technical assistance and financing to countries so
they can move towards effective and sustainable health
systems that deliver improved health services for all. We
will pursue this with the active engagement of developing
countries, the global health community, all development
partners and civil society partners.
Building on past successes and ongoing efforts, we can
and must do better -- together.
For more information, please contact:
World Health Organization
Joel Schaefer
Tel: +41-22-791-4473
Mobile: +41-79-516-4756
Email: schaeferj@who.int
GAVI Alliance
Jeffrey Rowland
Tel: +41-22-909-7165
Mobile: +41-79-240-4559
Email: jrowland@gavialliance.org
Global Fund
Jon Liden
Tel: +41-22-791-1723
Mobile: +41-79-244-6006
Email: jon.liden@theglobalfund.org
UNAIDS
Bret Brintzenhofe
Tel: +41-22-791-1698
Email: brintzenhofeb@unaids.org
United Nations Population Fund
Abubakar Dungus
UNFPA New York
Tel: +1-212-297-5031
UNICEF
Angela Hawke
Tel: +1-212-326-7269
Email: ahawke@unicef.org
World Bank
Phil Hay
Mobile: +1-202-409-2909
Email: phay@worldbank.org
All press releases, fact sheets and other WHO media
material may be found at: http://www.who.int .
2007'09.08.Sat
dotMobi Launches Next-Generation, Industry-Leading Mobile Web Site Testing Tool
September 05, 2007
Lauded as a 'Great Resource for Mobile Web Developers,'
Upgraded ready.mobi Tool Offers Site-wide Testing, a New
Design and Integrated Account Management for Developers
DUBLIN, Ireland, and WASHINGTON, Sept. 5
/Xinhua-PRNewswire/ -- dotMobi, the consortium behind the
only Internet address created specifically for mobile
phones, today launched an upgraded version of ready.mobi,
its free, industry-leading mobile Web test tool.
Already lauded as a "great resource for mobile Web
developers" by WAP Review (http://wapreview.com), the
2.0 version of ready.mobi (located at http://ready.mobi )
evaluates the quality of mobile Web sites using mobile
industry standards and best practices to ensure sites work
on all mobile phones around the world.
ready.mobi generates free reports with easy-to-evaluate
scores for every page on a mobile site, as well as in-depth
analysis of more than 35 attributes to determine how well a
site is likely to perform on mobile phones.
In addition, users of dotMobi's Developer Forum
(http://dev.mobi) are able to maintain ready.mobi test
preferences and a history of previous test results to show
the improvement of sites over time. This allows ready.mobi
to become an important part of the users' mobile Web
development and quality assurance processes.
Andy Moore, Director, Palace Marketing, Ltd.
(http://palacemarketing.mobi) said, "The new features
of ready.mobi allow me to run a check on an entire site.
The new interface makes it much quicker and easier to
assess how ready a site is. And the complete
site-processing feature is a great time saver. I can
initiate a crawl, then return later and view a complete
profile of how 'ready' the site is. The reports give a
bigger picture to the readiness of a site, save me time and
save my clients money."
WAP Review noted that ready.mobi's ability to check a
complete site is "nothing short of amazing."
The new version of ready.mobi delivers many
user-requested features, including additional mobile phone
emulators, the ability to specify mobile device headers to
crawl sites (and save them for later use), and color-coded
results that provide at-a-glance views with an option to
"drill down" to greater detail for each
attribute. Developers who build .mobi sites also have the
ability to stop and start the site crawlers and review
results in real-time.
"I've never seen such a human-friendly validation
tool," said Andy Moore of Palace Marketing. "The
'help me fix it' links are fantastic and provide
comprehensive, easily digestible guides on how to achieve
mobile readiness. It's not just a tool for geeks. It gives
an easy to understand, human-focused view on how ready a
site is."
Launched in November 2006, ready.mobi has already been
used to test more than 250,000 pages of mobile content,
ensuring that sites are of the highest quality for mobile
consumers.
"ready.mobi has proven to be incredibly popular
with the mobile developer community," said Neil
Edwards, CEO of dotMobi. "Being able to take the
feedback of the community and offer an advanced version -
still at no cost - to users is gratifying to dotMobi. The
high level of use and discussion around ready.mobi and our
Developer Forum at http://dev.mobi proves that interest in
creating .mobi content and services is growing daily."
About dotMobi
dotMobi (the informal name of mTLD Top Level Domain,
Ltd.), a consortium based in Dublin, Ireland with offices
in Washington, DC and Beijing, is leading the growth of
Internet use from mobile phones with the .mobi domain name.
Unique among domain name providers, dotMobi ensures that
services and sites developed on the .mobi domain are
optimized for use by mobile phones. On-the-go consumers can
have confidence that an Internet site will work on their
mobile phones when using a .mobi address.
dotMobi is backed by leading mobile operators, network
& device manufacturers, and internet content providers,
including Ericsson, GSM Association, Hutchison 3, Microsoft,
Nokia, Orascom Telecom, Samsung Electronics, Syniverse,
T-Mobile, Telefonica Moviles, TIM, Visa and Vodafone.
dotMobi is also a sponsor of W3C's Mobile Web Initiative.
For more information on dotMobi domains and
registration information, visit http://mtld.mobi . Visit
the dotMobi blog at http://blog.mobi .
For more information, please contact:
Vance Hedderel
dotMobi (mTLD Top Level Domain, Ltd.)
Tel: +1-703-485-5563
Email: vhedderel@mtld.mobi
Danielle Siemon
A&R Edelman for dotMobi
Tel: +1-650-762-2947
Email: danielle.siemon@edelman.com
2007'09.08.Sat
Freeborders Unveils Expansion Plans in China
September 05, 2007
SHENZHEN, China, Sept. 5 /Xinhua-PRNewswire/ --
Freeborders Incorporated, widely recognized as the #1
provider of technology solutions from China to global
clients, has just expanded operations in China.
Freeborders currently has a state of the art technology
center in Shenzhen, which has provided IT outsourcing
services to Fortune 1000 US and European companies for
nearly a decade. The company has expanded operations and
has opened a new office in Guangzhou. This move gives
Freeborders much needed additional space and positions them
closer to key clients.
This expansion will help to facilitate Freeborders'
growth, provide additional business continuity capability,
and allow Freeborders to gain access to an additional
talent pool in Guangzhou. Because of significant demand for
Freeborders IT outsourcing services, the company is also
evaluating additional locations for expansion over the next
12-18 months. Locations such as Xian, Chengdu and others are
under consideration.
Jim Reesing, Freeborders Executive Vice President for
Global Sales and Operations, explained the drivers of
Freeborders growth. "Our unique global operating mode,
CHINDUS(sm), has contributed significantly to our growth and
need for additional locations. The CHINDUS(sm) approach
includes adopting best practices from the US, India, and
China. From the US, we leverage our strong on site domain
knowledge, our strong US management team, and our
relationship management capabilities. From India, we adopt
industry best practices around governance and the global
delivery model. From China, we leverage the massive talent
pool, the strong technical skills, and the English language
capabilities that China can deliver."
Industry leaders and analysts agree that China is the
next big destination in offshore sourcing strategies. It's
unparalleled wealth of highly skilled labor and solid
infrastructure place it atop most "short" lists
for offshoring engagements.
"As more and more Fortune 1000 companies take
advantage of a multi-country sourcing strategy, China is
becoming the most compelling choice," Jim adds.
"The opening of our Guangzhou facitily is symbolic of
the growth and scale we are seeing across the China
market"
About Freeborders
Freeborders is a US-based, global provider of
outsourcing solutions with development centers in China.
The company specializes in a broad spectrum of information
technology and information technology enabled services. Its
state-of-the-art infrastructure, proven global delivery
model, experienced management team, and highly skilled
colleagues deliver to its clients award-winning customer
support and quality. Freeborders is assessed at Level 5 of
the SEI's CMMI, and is ISO 27001 as well as ISO 9901-2000
certified. To learn more, visit http://www.freeborders.com
.
For additional information, please contact:
Joe Gutierez
Freeborders
Tel: +1-415-433-4700 x224
Mobile: +1-415-254-6430
Email: joe.gutierez@freeborders.com
Mike Chen
Freeborders
Tel: +86-755-2661-0445
Mobile: +86-135-1084-6478
Email: mike.chen@freeborders.com
2007'09.08.Sat
Arrow to Showcase Turnkey Solutions at Freescale IDH Solutions Show
September 05, 2007
HONG KONG, Sept. 5 /Xinhua-PRNewswire/ -- Arrow Asia
Pac Ltd., a business unit of Arrow Electronics, Inc. (NYSE:
ARW), announced it will showcase a number of turnkey
independent design house (IDH) solutions at the Freescale
Solutions Show to be held in Shenzhen, China, on Sept. 7,
2007.
(Logo: http://www.xprn.com/xprn/sa/200703021139.JPG )
Arrow Asia will present hands-on demonstrations of
solution platforms for devices including MP4, iPOD smart
dock, personal global positioning system (GPS) navigation,
portable media player (PMP) and WiFi VoIP phones. In
addition, Arrow's IDH partners will showcase low-cost
portable navigation, E-Bike controller and portable DTV
multimedia solutions.
"Partnering with more than 45 IDH partners in the
Asia-Pacific region, Arrow is well positioned to help
customers find innovative and turnkey solutions that will
accelerate time-to-market and gain design
flexibility," said CC Lim, vice president of marketing
for Arrow Asia Pac. "Participants of this event will
gain advanced knowledge on new concepts, design techniques
and innovative technologies."
Organized by Freescale Semiconductor with the support
of distributors and design engineers and consultants, the
Freescale IDH Solutions Show will showcase various
industry-leading solutions using devices from Freescale.
The solutions on exhibit will range in various application
areas, including networking, home appliance, consumer,
multimedia and wireless connectivity.
About Arrow Asia Pac
A business unit of Arrow Electronics, Inc. (NYSE: ARW),
Arrow Asia Pac is one of Asia-Pacific's leading electronic
component distributors. In addition to its regional
headquarters in Hong Kong, Arrow Asia Pac operates 50 sales
offices, four primary distribution centers and 12 local
warehousing facilities in 11 countries/territories across
Asia.
Providing a full range of semiconductors, passive,
electromechanical and connector products from over 170
leading international and local suppliers, Arrow Asia Pac
serves more than 10,000 original equipment and contract
manufacturers and commercial customers in Asia-Pacific.
Visit us at http://www.arrowasia.com .
For more information, please contact:
Ray Leung
Marketing Communications Director
Arrow Asia Pac Ltd.
Tel: +852-2484-2484
Email: marcom.asia@arrowasia.com
Grace Kung
Marketing Communications Manager
Tel: +852-2484-2682
Email: grace.kung@arrowasia.com
2007'09.08.Sat
Data Affirm Benefit of ALIMTA(R) (pemetrexed for injection) for Patients With Malignant Pleural Mesothelioma
September 05, 2007
ALIMTA-based Regimens Continue to Support Patients with
Devastating Disease
SEOUL, South Korea, Sept. 5 /Xinhua-PRNewswire/ -- Data
from two large, open-label studies show patients experienced
one-year survival rates above 50 per-cent when treated with
ALIMTA(R) (pemetrexed for injection) or ALIMTA-based
regimens for malignant pleural mesothelioma (MPM) in both a
first-line and second-line setting. The study results
affirm important efficacy and safety benefits for Eli Lilly
and Company's ALIMTA, the only-known agent to demon-strate a
survival benefit in this often difficult-to-treat disease
primarily associated with exposure to asbestos. The data
were presented today at the 12th World Conference on Lung
Cancer.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
One of the largest studies undertaken in the treatment
of mesothelioma, the triple-arm, open-label, multicenter,
first-line study (WCLC Abstract # C5-01) treated patients
with ALIMTA as a single agent, while the other two arms
evaluated ALIMTA in combination with either cisplatin or
carboplatin. All three arms demonstrated clinically
similar one-year survival rates (58.6% for ALIMTA alone;
63.1% for ALIMTA+cisplatin, and; 64.0% for
ALIMTA+carboplatin). The ALIMTA plus platinum combination
arms achieved higher response rates than ALIMTA alone
(10.5% for ALIMTA; 26.3% for ALIMTA+cisplatin, and; 21.7%
for ALIMTA+carboplatin). All 2,023 patients treated in the
first-line setting had a histologic or cytologic diagnosis
(pa-tients cells were reviewed under a microscope) of MPM
that was not amenable to curative surgery.
An open-label, multicenter study (WCLC Abstract #
C5-03), evaluated the results from 988 patients who were
treated in a second-line setting for MPM with ALIMTA as a
single agent, ALIMTA+cisplatin or ALIMTA+carboplatin after
being previously treated with chemotherapy. All three arms
demonstrated a significant one-year survival rate (54.7% for
ALIMTA alone; 67.9% for ALIMTA+cisplatin, and; 65.5% for
ALIMTA+carboplatin). Patients treated with ALIMTA in
combination with a platinum-based chemotherapy demonstrated
higher response rates (12.1% for ALIMTA; 23.8% for
ALIMTA+cisplatin, and; 16.8% for ALIMTA+carboplatin). The
most common grade 3/4 toxicities on both studies were
leukopenia, neutropenia, thrombocytopenia and anemia.
"The initial clinical trial results for ALIMTA in
malignant pleural mesothelioma were definitely considered a
medical breakthrough when they were unveiled just three
years ago," said Richard Gaynor, M.D., vice president,
cancer research and global oncology platform leader for
Lilly. "It is encouraging that these open-label
studies show real world patient treatment outcomes that are
consistent with those from the controlled clinical research
environment. In my opinion, this is clinically meaningful
information to the practicing oncologist."
ALIMTA was approved by both the European Medicines
Agency (EMEA) and the U.S. Food and Drug Administration
(FDA) in 2004 in combination with cisplatin for the
treatment of MPM. To date, ALIMTA has been approved in
more than 85 countries in combination with cisplatin for
the treatment of MPM.
Mesothelioma
Malignant pleural mesothelioma is a rare cancer of the
lining of the lungs. The disease is often associated with
asbestos exposure and has a long latency period -- usually
between 20 and 40 years. Most people are not diag-nosed
until the cancer is in advanced stages and treatment with
surgery or ra-diation is not an option.
ALIMTA ABBREVIATED PRESCRIBING INFORMATION
Uses
ALIMTA is indicated in combination with cisplatin for
the treatment of chemotherapy naive patients with
unresectable malignant pleural mesothelioma. ALIMTA is
indicated as monotherapy for the treatment of patients with
locally advanced or metastatic non-small cell lung cancer,
after prior chemotherapy.
Dosage and Administration
The drug is to be administered intravenously, under the
supervision of a physician qualified in the use of cytotoxic
anti-cancer therapy.
Malignant pleural mesothelioma: Pemetrexed in
combination with cisplatin has been investigated using a
three-week (21-day) cycle. Pemetrexed is used at 500 mg/m2
of body surface area (BSA), given by ten-minute infusion, on
day 1 of each 21-day cycle. Cisplatin is used at 75 mg/m2
BSA, given by two-hour infusion, approximately 30 minutes
after completion of the pemetrexed infusion on day 1 of
each cycle. Adequate anti-emetic treatment and hydration
for cis-platin treatment must be given.
Non-small cell lung cancer: The recommended dose of
pemetrexed is 500 mg/m2 BSA, given by ten-minute infusion,
on day 1 of each 21-day cycle.
Pre-medication: Supplement with 1000 micrograms
intramuscular vitamin B12 and oral folic acid (350 to 1000
micrograms) to reduce toxicity (for full de-tails see
Summary of Product Characteristics [SPC]). To reduce the
incidence and severity of skin reactions, a corticosteroid
should be given the day prior to, on the day of, and the
day after pemetrexed administration -- this should be
equivalent to 4mg of dexamethasone administered orally
twice a day.
Monitoring: Monitor prior to each dose for complete
blood cell count, in-cluding a differential white cell
count and platelet count. Absolute neutro-phil count
should be greater than or equal to 1,500 cells/mm3 and
platelets greater than or equal to 100,000 cells/mm3.
Prior to each dose, collect blood chemistry tests to
evaluate renal and hepatic function. Dose adjustments to
pemetrexed and/or cisplatin at the start of a subsequent
cycle should be based on nadir haematological counts or
maximum non-haematological toxicity. If necessary, delay
or withhold treatment in the presence of haematological
tox-icity, neurotoxicity, and/or impaired hepatic/renal
function. (For full in-formation on dose modification see
SPC.)
Children and adolescents: Not recommended for use in
patients under 18 years of age.
Renal impairment: Patients with creatinine clearance
greater than or equal to 45 ml/min require no dose
adjustment other than those recommended for all patients.
Use in patients with creatinine clearance below 45 ml/min
is not recommended. See also Warnings and Special
Precautions.
Hepatic impairment: Patients with hepatic impairment,
such as bilirubin >1.5-times the upper limit of normal
and/or transaminase >3.0-times the upper limit of normal
(hepatic metastases absent) or >5.0-times the upper limit
of normal (hepatic metastases present), have not been
specifically studied.
Contra-indications
Hypersensitivity to pemetrexed or to any of the
excipients. Concomitant yellow fever vaccine.
Breast-feeding.
Warnings and Special Precautions
Myelosuppression is usually the dose-limiting toxicity.
Patients must be instructed to take folic acid and vitamin
B12 as a prophylactic measure. Pre-treatment with
dexamethasone (or equivalent) can reduce the incidence and
se-verity of skin reactions. Serious renal events,
including acute renal failure, have been reported with
pemetrexed alone or in combination with other
chemo-therapeutic agents. Many of the patients in whom
these occurred had underly-ing risk factors including
dehydration or pre-existing hypertension or diabe-tes. In
patients with clinically significant third space fluid,
consideration should be given to draining the effusion
prior to administration. Serious cardiovascular events,
including myocardial infarction and cerebrovascular events,
have been uncommonly reported when pemetrexed is given in
combination with other cytotoxic agents; most of these
patients had pre-existing cardio-vascular risk.
Concomitant use of live attenuated vaccines is not
recom-mended.
Interactions
Concomitant administration of nephrotoxic drugs and
substances that are also tubularly secreted could
potentially result in delayed clearance of pe-metrexed. If
necessary, creatinine clearance should be closely monitored.
Patients must avoid taking non-steroidal anti-inflammatory
drugs (NSAIDs) with long elimination half-lives for at
least 5 days prior to, on the day, and at least 2 days
following pemetrexed administration. In patients with
normal re-nal function (creatinine clearance greater than
or equal to 80 ml/min), high doses of NSAIDs (such as
ibuprofen >1600 mg/day) and aspirin at higher dosage
(greater than or equal to 1.3 g daily) may decrease
pemetrexed elimination and increase the occurrence of
adverse events. Patients with mild to moderate re-nal
insufficiency (creatinine clearance from 49 to 79 ml/min)
should avoid taking NSAIDs (e.g., ibuprofen) or aspirin at
higher dosage, for 2 days be-fore, on the day of, and 2
days following pemetrexed administration.
There is a possible interaction between oral
anticoagulants and pe-metrexed; therefore, increase the
frequency of International Normalised Ratio monitoring
(INR) if treating with oral anticoagulants.
Pregnancy and Lactation
Avoid in pregnancy and do not use in breast-feeding
women.
Pemetrexed can be genotoxic; sexually mature males are
advised not to fa-ther a child during treatment and up to 6
months thereafter. Owing to the possibility of irreversible
infertility, men are advised to seek counselling on sperm
storage before starting treatment. Women of childbearing
potential must use effective contraception during
treatment.
Driving, etc
It has been reported that pemetrexed can cause
somnolence. Patients should be cautioned against driving
or operating machinery.
Undesirable Effects
Haematological: Very common: Anaemia, leucopenia,
thrombocytopenia, neu-tropenia. Common: Febrile
neutropenia and infection without neutropenia. Un-common:
Pancytopenia.
Gastro-intestinal: Very common: Nausea, vomiting,
stomatitis/pharyngitis, anorexia, diarrhoea, constipation.
Common: Dyspepsia, abdominal pain. Rare: Colitis.
General: Very common: Fatigue. Common: Fever,
conjunctivitis.
Metabolism and nutrition: Common: Dehydration.
Nervous system: Very common: Neuropathy - sensory.
Common: Neuropathy - motor, dysgeusia.
Renal and urinary: Very common: Creatinine elevation,
creatinine clearance decreased. Common: Renal failure.
Hepatobiliary: Common: SGPT (ALT) elevation and SGOT
(AST) elevation, in-creased GGT. Rare: Cases of hepatitis,
potentially serious, have been re-ported during trials.
Skin and subcutaneous tissue: Very common:
Rash/desquamation, alopecia. Common: Urticaria, allergic
reaction/hypersensitivity, erythema multiforme, pruritus.
Cardiovascular and cerebrovascular: Uncommon:
Myocardial infarction, an-gina pectoris, cerebrovascular
accident, arrhythmias, transient ischaemic at-tack.
(Usually when given in combination with other cytotoxic
agents and with pre-existing cardiovascular risk.) Common:
Chest pain.
For full details of these and other side-effects,
please see the Summary of Product Characteristics, which is
available at http://emc.medicines.org.uk/ .
About Lilly Oncology, a Division of Eli Lilly and
Company
For more than four decades, Lilly Oncology has been
collaborating with cancer researchers to deliver innovative
treatment choices and valuable pro-grams to patients and
their physicians. Inspired by courageous patients living
with cancer, Lilly Oncology is providing treatments that
are considered global standards of care and developing a
broad portfolio of novel targeted therapies to accelerate
the pace and progress of cancer care.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is
developing a growing portfolio of first-in-class and
best-in-class pharmaceutical products by ap-plying the
latest research from its own worldwide laboratories and
from col-laborations with eminent scientific organizations.
Headquartered in Indianapo-lis, Ind., Lilly provides answers
-- through medicines and information -- for some of the
world's most urgent medical needs.
P-LLY
ALIMTA(R) (pemetrexed for injection), Lilly
This press release contains forward-looking statements
about the potential of ALIMTA for the treatment of
malignant pleural mesothelioma and reflects Lilly's current
beliefs. However, as with any pharmaceutical products under
development, there are substantial risks and uncertainties
in the process of development, commercialization, and
regulatory review. There is no guarantee that the products
will receive additional regulatory approvals. There is also
no guarantee that the products will continue to be
commercially successful. For further discussion of these
and other risks and uncertainties, see Lilly's filings with
the United States Securities and Exchange Commission. Lilly
un-dertakes no duty to update forward-looking statements.
For more information, please contact:
Gregory L. Clarke, Lilly
Mobile: +1-317-554-7119
Email: gregory.clarke@lilly.com
Chantal Samonte
CPR Worldwide
Mobile: +1-202-550-4129
Email: c.samonte@cprworldwideusa.com
2007'09.08.Sat
SMB & Galephar Select Liquent Technology to Streamline Submission Publishing
September 05, 2007
Insight Publisher Is Industry's Only eCTD Solution Built On
Integrated Regulatory Information Management Platform
PHILADELPHIA and LONDON, Sept. 5 /Xinhua-PRNewswire/ --
Liquent, a Thomson business and global leader in providing
regulatory software solutions, information products and
related services for the life sciences industry, today
announced that SMB & Galephar has selected InSight
Publisher to streamline its regulatory platform. InSight
Publisher is designed to accelerate the publishing process
for drug submissions to the world's regulatory authorities.
InSight Publisher will enable SMB to create all the
components of both electronic and paper submissions from a
single assembly structure, enhancing efficiency and helping
to bring new drugs to the market faster. InSight Publisher
is built on the same platform as InSight Manager which
offers sophisticated registration management and submission
tracking capabilities and the entire platform is adaptable
to many different organizational processes and designs,
including centralized and decentralized publishing.
"The constantly changing regulatory framework
makes it more difficult than ever to develop and register
pharmaceutical products," said Philippe Baudier, SMB's
CEO. "We're confident that InSight Publisher will
shorten our time from finalized documents to the complete
eCTD -- making complex compliance simple and
seamless."
InSight Publisher also provides other new features to
accelerate drug applications:
-- Step-by-step wizards for eCTDs and study reports
help to streamline
the creation of submissions and reports that comply
with ICH,
Japanese, Canadian, US and other regional
specifications;
-- The most complete eCTD Conformity Checking that
automatically performs
50 eCTD validation checks, including 32 ICH
compliance requirements;
-- Templating capabilities that let companies
pre-define the structure of
their content and the placement of paper publishing
elements such as
tabs, slip sheets and cover pages;
-- An eCTD import wizard that helps organizations to
continue their
lifecycle management of previously completed eCTD
submissions.
"Liquent's InSight Publisher is the leading
product in regulatory publishing," said Jim Nichols,
Liquent's vice president of Product Strategy and Marketing.
"Our one-of-a-kind technology is sure to save SMB
critical time throughout their publishing process."
Additional information about InSight Publisher is
available at http://www.liquent.com .
About Liquent Regulatory Solutions
Liquent regulatory solutions provide software,
information products, and related services for the life
sciences industry. These solutions and services help ensure
clients meet the strict standards of regulatory authorities
across the world helping them achieve quality, accuracy,
and data integrity to deliver regulatory reports and
submissions reliably and on time. In addition to technology
and services, the Liquent IDRAC database service provides
the most comprehensive intelligence on the drug and
biologics regulatory environment in 38 of the largest
markets in the world.
As a result, 48 of the top 50 global life sciences
companies rely on Liquent regulatory solutions to stay
current with the latest intelligence and to provide the
technology and services to compress the regulatory
submissions and approval process, improving speed to
market, cost control, and productivity, all of which
contribute to ensuring patients' and physicians' timely
access to new drugs. Over the last decade, more than 5,000
regulatory submissions have been produced using Liquent
world-class products and expert services. For more
information please visit, http://www.liquent.com .
About The Thomson Corporation
The Thomson Corporation ( http://www.thomson.com ) is a
global leader in providing essential electronic workflow
solutions to business and professional customers. With
operational headquarters in Stamford, Conn., Thomson
provides value-added information, software tools and
applications to professionals in the fields of law, tax,
accounting, financial services, scientific research and
healthcare. The Corporation's common shares are listed on
the New York and Toronto stock exchanges (NYSE: TOC; TSX:
TOC).
Thomson Scientific is a business of The Thomson
Corporation. Its information solutions assist professionals
at every stage of research and development-from discovery to
analysis to product development and distribution. Thomson
Scientific information solutions can be found at
http://www.scientific.thomson.com .
For more information, please contact:
Sue Besaw
Thomson Scientific
Phone: +1-215-823-1840
Email: susan.besaw@thomson.com
Website: http://www.liquent.com
http://www.scientific.thomson.com
http://www.thomson.com
2007'09.08.Sat
WISeKey Announces Strong Growth of its Global Trusted Affiliate Network
September 05, 2007
GENEVA and DALIAN, China, Sept. 5 /Xinhua-PRNewswire/
-- Selected by the World Economic Forum as one of the top
500 mould-breaking companies New Champions, WISeKey is
present at the Inaugural Annual Meeting of the New
Champions in Dalian China and announces today that new
WISeKey Affiliates are now in the process of being
established in Argentina, Benelux, Brazil, Chile, China,
Colombia, Egypt, France, Germany, Hungary, Italy, Lebanon,
Mexico, Monaco, Morocco, Peru, Saudi Arabia, Sweden,
Turkey, UAE, Uruguay, USA, and Venezuela.
WISeKey's Global Affiliate Network consists of local
service providers operational at national level that are
nodes for the deployment of trusted communities online.
These Affiliates use WISeKey's standards-based technology,
products, operating practices and trusted security
infrastructures to deliver globally interoperable trust
services over the Internet. In essence, it is like the GSM
standard for identity and trust online.
WISeKey has entered the mass market with a solution
with universal appeal distributed by a global network of
trusted affiliates.
"By combining their national expertise, powerful
brands and strong customer relationships with our Trusted
Security technologies and services, we are well positioned
to enable a wide range of trusted secure services and
interactions on a global basis. Our network of global
trusted affiliates now includes one of the most attractive
affiliated networks on the Internet including government
agencies, national leading telecommunications companies and
e-commerce service providers," stated Carlos Moreira,
Chairman and CEO of WISeKey.
Internet: http://www.wisekey.com
For more information, please contact:
Sophia Boeckh,
Corporate Communications Officer
Tel: +41-22-594-30-00
Email: sboeckh@wisekey.com
2007'09.08.Sat
Green Tomato Ltd. Named as 'Red Herring 100 Asia' Award Winner for 2007
September 05, 2007
The 100 Most-Promising Private Technology Ventures
Celebrated at Event in Hong Kong, China
HONG KONG, Sept. 5 /Xinhua-PRNewswire/ -- Red Herring
Magazine announced today that Green Tomato Ltd. has been
selected as a winner of the prestigious Red Herring 100
Asia 2007 awards. The news was announced at a gala dinner
during the Red Herring 100 Asia event in Hong Kong on
August 29.
Winners were selected from a pool of more than 500
applicants based in 16 countries/regions including China,
India, Japan, Singapore, Korea, Australia and Vietnam. The
names of the winners can be found online at
http://www.herringevents.com/asia07/index.html .
The Red Herring editorial team carefully selected the
winning companies based on both quantitative and
qualitative criteria such as financial performance,
technology innovation, quality of management, execution of
strategy, and integration into their ecosystem.
"After a rigorous evaluation process, we're very
happy with the winners we selected," said Joel
Dreyfuss, Editor-in-Chief of Red Herring. "There was
a large pool to choose from and we're impressed by the
caliber and innovative talent bursting from Asia's business
and technology sector."
"We are very honored to be selected as one of the
winners for the Red Herring Asia 100, this is another great
endorsement of ourselves and our products from the industry.
This is the ninth award we have received in the last 3
years, it is an important endorsement for the company to
continuously deliver quality and innovative products that
meet with the needs of our customers and partners,"
said Arthur Chang, CEO of Green Tomato Ltd.
Red Herring 100 Asia is an exclusive event honoring 100
cutting-edge private technology companies from across the
Asia-Pacific region. Distinguished speakers on Red
Herring 100 Asia include Richard Li, Chairman of PCCW; John
Chen, Chairman of Sybase.
About Green Tomato Ltd.
Green Tomato Ltd ( http://www.gtomato.com ) enables
mobile operators, media, handset manufacturers, content
providers and any organisation who would like to expand
their presence and build their user community on mobile
space. We provide one-stop service ranging from Mobile
Platform Solution to Mobile Value-added content.
Based in Hong Kong with offices in China, Green Tomato
has enabled mobile communities of over 700,000 users,
distributing through more than 30 mobile operators and
service providers in Asia with a potential use base over
30M.
Green Tomato has consistently delivered many innovative
mobile applications in the region and has been highly
recognized by the industry worldwide. These include Global
Mobile Content Award in Korea, Forum Nokia PRO Awards, the
Asia Pacific ICT Awards and China Mobile (Guangzhou)
Innovative Application Award, Hong Kong Digital
Entertainment Award and Wireless Technology Excellence
Award.
About Red Herring
Red Herring is a global media company uniting the
world's best high technology innovators, venture investors
and business decision makers in a variety of forums: a
leading innovation magazine; an online daily technology
news service; technology research, and major events for
technology leaders around the globe. Red Herring provides
an insider's access to the global innovation economy,
featuring unparalleled insights on the emerging
technologies driving the economy. For more information,
visit http://www.redherring.com .
For more information, please contact:
Contact at Green Tomato Ltd.:
Sue Wong
Marketing Executive
Tel: +852-2866-0084
Email: sue.wong@gtomato.com
Contact at Red Herring:
Maggie Xiao
Director, Red Herring APAC
Tel: +1-650-585-3419
Email: mxiao@redherring.com
2007'09.08.Sat
BLOOMBERG TELEVISION Explores Asia's Environmental Challenges
September 05, 2007
'A Greener Asia' Debuts on the 'Bloomberg Live' Program
NEW YORK, Sept. 5 /Xinhua-PRNewswire/ -- Starting
tomorrow on the BLOOMBERG TELEVISION(R) program
"Bloomberg Live," anchor Bernard Lo will host a
new regular segment, "A Greener Asia." With
in-depth reports and exclusive interviews from Bloomberg
news bureaus across the region, "A Greener Asia"
will look at how businesses and governments in Asia are
responding to environmental challenges.
The new BLOOMBERG TELEVISION segment will explore such
topics as China's battle with pollution in the lead up to
the Beijing Olympics in 2008 and "Green Funds" -
investment vehicles specializing in renewable energy and
other environmental business initiatives.
"A Greener Asia" will debut Thursday,
September 6th on "Bloomberg Live" at 7:40am Hong
Kong/Singapore, 8:40am Tokyo and 9:40am Sydney.
This exclusive news and follow up reports are available
to the public on BLOOMBERG TELEVISION and BLOOMBERG RADIO(R)
services worldwide, as well as to users of the BLOOMBERG
PROFESSIONAL(R) service. Clips from the interviews will be
archived and available via the BLOOMBERG PROFESSIONAL
service.
About Bloomberg Television
The BLOOMBERG TELEVISION(R) network is the only
worldwide 24-hour business and financial network, produced
and distributed on 11 separate channels in seven languages.
BLOOMBERG TELEVISION programming is created and supported by
the global BLOOMBERG NEWS(R) service with more than 2,300
professionals in over 130 bureaus.
About Bloomberg
Bloomberg is the leading global provider of data, news
and analytics. The BLOOMBERG PROFESSIONAL(R) service and
Bloomberg's media services provide real-time and archived
financial and market data, pricing, trading, news and
communications tools in a single, integrated package to
corporations, news organizations, financial and legal
professionals and individuals around the world.
Bloomberg's media services include the global BLOOMBERG
NEWS(R) service with more than 2,300 professionals in over
130 bureaus worldwide; the BLOOMBERG TELEVISION(R) 24-hour
business and financial network produced and distributed
worldwide on eleven separate channels in seven languages;
and BLOOMBERG RADIO(R) services which provide
up-to-the-minute news on XM, Sirius and WorldSpace
satellite radio around the world and on WBBR 1130AM in New
York. In addition, Bloomberg publishes BLOOMBERG MARKETS(R)
magazine and BLOOMBERG PRESS(R) books for investment
professionals. For more information please visit
http://www.bloomberg.com.
For more information, please contact:
Heidi Tan
Bloomberg LP
Phone: +1-212-617-5375
Email: htan14@bloomberg.net
Website: http://www.bloomberg.com
2007'09.08.Sat
Freescale Retains Colliers ATREG to Sell UK Manufacturing Facilities in East Kilbride and Dunfermline
September 05, 2007
Operational Wafer Manufacturing Facility and Wafer
Manufacturing Shell Offer Additional Capacity,
Diversification and Development Opportunities
SEATTLE, Sept. 4 /Xinhua-PRNewswire/ -- Freescale
Semiconductor has retained Colliers ATREG, in conjunction
with Colliers CRE in Scotland, to assist with the sale of
its two wafer manufacturing facilities in the United
Kingdom. The facilities include an operational 150-mm
semiconductor manufacturing facility in East Kilbride and a
200-mm wafer fabrication shell in Dunfermline.
Freescale's 25 acre East Kilbride site features a
0.35-micron capable volume wafer manufacturing facility,
including a 92,000-square-foot (8,547 m2) wafer fab
cleanroom, and approximately 700 advanced process tools.
For over 20 years this well maintained, centrally located
facility has produced volume, high quality automotive
semiconductor products and leading edge power devices for
the networking and wireless communication industries.
Property website: http://www.atreg.com/freescale1.
Freescale's 150 acre Dunfermline site includes a
1-million-square-foot (93,000 m2) facility shell
constructed in 1997 but not fully completed and never
occupied. Some facility infrastructure is on-site, but
non-operational. This allows users the ability to
customize and complete the infrastructure to meet the
requirements of their specific operations. Property
website: http://www.atreg.com/freescale2.
"Our team of global semiconductor market
specialists is implementing a worldwide campaign to reach
all potential semiconductor and advanced technology
users," said Doug Barrett, Colliers senior vice
president and director of ATREG. "Both facilities
offer significant cost and time-to-market advantages for a
producer seeking additional capacity, or who wishes to
manufacture a more diverse or advanced range of
semiconductor devices."
"Freescale has retained Colliers ATREG because of
their global track record in selling semiconductor
facilities as going concerns," said Greg Heinlein,
Freescale vice president and treasurer. "Freescale is
seeking buyers who can fully realize the inherent value of
these first class manufacturing facilities."
For additional information regarding these facilities,
please contact Colliers at 206.223.0206 (USA) or [44] (131)
240-7514 (UK).
About Freescale
Freescale Semiconductor is a global leader in the
design and manufacture of embedded semiconductors for the
automotive, consumer, industrial, networking and wireless
markets. The privately held company is based in Austin,
Texas, and has design, research and development,
manufacturing or sales operations in more than 30
countries. Freescale is one of the world's largest
semiconductor companies with 2006 sales of $6.4 billion
(USD). http://www.freescale.com
About Colliers ATREG
Colliers International is one of the top three
commercial real estate services firms in the world with
more than 9,300 employees in 267 offices in 57 countries.
Seattle-based Colliers ATREG helps companies buy and sell
advanced technology assets. Recently, Colliers ATREG has
represented IBM, LSI Logic, Sony, Maxim, Fujitsu and
Matsushita in sales and acquisitions of cleanroom
manufacturing, fab and technology facilities.
http://www.atreg.com
About Colliers CRE
Colliers CRE is one of the UK's top-ten real estate
advisory firms, providing agency, development, management,
investment and professional services across a wide range of
business sectors. Colliers CRE works with public and private
sector clients, from retailers and property companies to
international corporations and pension funds, on projects
which span the UK and Europe. Colliers CRE has 700 staff,
working from 14 offices across the UK and is part of
Colliers International, one of the world's leading real
estate organizations.
For more information, please contact:
Colliers
Doug Barrett
Phone: +1-206-223-0206
Email: doug.barrett@colliers.com
Stephen Rothrock
Phone: +1-206-287-4757
Email: stephen.rothrock@colliers.com
Bryce Stewart
Phone: +44-0-1312-407514
Email: bryce.stewart@collierscre.co.uk
Website: http://www.colliers.com
http://www.atreg.com
Freescale Semiconductor
Robert Hatley
Phone: +1-512-996-5134
Email: robert.hatley@freescale.com
Dawn Bliss
Phone: +44-0-1355-355240
Email: dawn.bliss@freescale.com
2007'09.08.Sat
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
September 05, 2007
SEOUL, South Korea, Sept. 5 /Xinhua-PRNewswire/ --
Patients worldwide with advanced lung cancer can expect
longer survival according to new data from the TRUST study
presented at the 12th World Conference on Lung Cancer
(WCLC) in Seoul, Korea. These new worldwide observations
show that patients suffering from non-small cell lung
cancer (NSCLC) and treated with Tarceva (erlotinib) in
routine clinical practice are experiencing longer life.
The results from TRUST reinforce the benefits that patients
experienced in the landmark BR.21 study that earned Tarceva
its approval in over 80 countries. Non-small cell lung
cancer is the most common form of lung cancer suffered by
over one million people worldwide.
In BR.21, 31% of patients receiving Tarceva were alive
at one year compared to 22% in the placebo arm and patients
experienced a 42.5% improvement (6.7 months vs. 4.7 months)
in length of survival. In TRUST, data from 6,181 patients
reported a median overall survival of 7.5 months. Data on
the remaining patients are still being analyzed and will be
announced at a later date.
"The increased survival time in patients from
TRUST reinforces what we are seeing in our clinical
practices," said Professor Tony Mok of the Department
of Clinical Oncology, Chinese University of Hong Kong.
"These new data further underscore the drug's
potential across a broad range of lung cancer patients and
show that Tarceva enables patients to spend more quality
time with their families and loved ones."
TRUST is the largest and longest ongoing study ever
conducted of Tarceva. It includes almost 12,000 patients
with advanced NSCLC in over 59 countries in Asia, Europe
and the Americas.
Over 182,000 patients worldwide have been treated with
Tarceva since it was launched three years ago. These latest
data reinforce that Tarceva is fulfilling its promise of
offering longer survival and better quality of life to a
broad range of patients - men, women, smokers, non-smokers
and people from a wide range of ethnic groups - with NSCLC,
one of the world's most deadly forms of cancer.
"TRUST demonstrates that even in routine clinical
practice Tarceva has comparable efficacy to BR.21,"
said Dr. Ulrich Gatzemeier, an investigator for TRUST at
the Department of Thoracic Oncology, Hospital
Grosshansdorf, Hamburg, Germany. "This is a great step
forward in the treatment of lung cancer, and one which will
offer hope to many patients and families affected by this
disease."
Roche's ongoing commitment to patients
Tarceva is currently being evaluated in an extensive
clinical development program on earlier stages of NSCLC by
a global alliance comprising OSI Pharmaceuticals, Genentech
and Roche. Under this program, almost 20 clinical studies
are being conducted with Tarceva to discover new ways to
further increase its life-extending benefits for patients
with lung and other types of cancer. Additionally, Tarceva
is being studied in combination with Avastin in NSCLC and
in a wide variety of other solid tumour types.
"TRUST is just one of the many major clinical
trials supported by Roche currently underway to help
identify those patients who can benefit the most from
treatment with Tarceva," said William M. Burns, CEO of
the Pharmaceuticals Division at Roche. "Our focus is to
improve survival rates and quality of life for people
suffering from all types of cancer."
For further information and all the latest news on
Tarceva and lung cancer please visit
http://www.tarcevapressoffice.com .
Notes to Editors
About TRUST
TRUST, the largest and longest ongoing study of Tarceva
in lung cancer worldwide, involves nearly 12,000 NSCLC
patients from 59 countries across Asia, the Middle East,
Europe and the Americas. It is a multi-center, global,
open-label study of Tarceva in lung cancer patients for the
second- or third-line treatment of advanced non-small cell
lung cancer (NSCLC). Also an expanded access program, TRUST
enabled thousands of patients worldwide with advanced NSCLC
to receive early access to Tarceva by filling the gap
between the submission date of the new drug application and
the date of final approval. Since TRUST started in 2004, 93%
of the participating countries received approval of Tarceva
as monotherapy for patients with advanced NSCLC.
About BR.21
EU approval for Tarceva was based on a pivotal Phase
III study - BR.21 - published in the New England Journal of
Medicine. BR.21 was conducted by the National Cancer
Institute of Canada Clinical Trials Group, in collaboration
with OSI Pharmaceuticals, with the participation of 86 sites
from 17 countries around the world. This study involved 731
patients with advanced NSCLC whose cancers had progressed
after first- or second-line chemotherapy and compared
patients receiving Tarceva monotherapy with placebo.
The key study results were:
-- Treatment with Tarceva in patients with advanced
NSCLC resulted in significantly longer survival compared to
placebo, a 42.5% improvement (6.7 months vs. 4.7 months).
-- 31% of patients receiving Tarceva were alive at one
year compared to 22% in the placebo arm.
-- Patients receiving Tarceva had stability or control
of their lung cancer-related symptoms such as cough,
shortness of breath and pain, for significantly longer.
-- Patients also had a superior quality of life and
improved physical function compared to those on placebo.
-- The benefits of Tarceva were shown in a broad
spectrum of patients.
About Tarceva
Tarceva is the first and only EGFR oral targeted agent
with proven and significant survival and symptom benefit in
a broad range of patients with advanced lung and pancreatic
cancer. Currently most lung and pancreatic cancer patients
are treated wholly with chemotherapy which can be very
debilitating due to its toxic nature. Tarceva works
differently to chemotherapy by specifically targeting
tumour cells, and avoids the typical side-effects of
chemotherapy.
Tarceva has been approved in the European Union since
September 2005 and in the US since November 2004 for the
treatment of patients with locally advanced or metastatic
NSCLC after failure of at least one prior chemotherapy
regimen. Furthermore, Tarceva, in combination with
chemotherapy, is the first treatment in over a decade to
have shown a significant survival benefit in treating
patients with pancreatic cancer. It is approved in the US,
in combination with gemcitabine, for the first-line
treatment of patients with locally advanced, unresectable
or metastatic pancreatic cancer and in the EU for treatment
of metastatic pancreatic cancer. Since its initial launch
three years ago, Tarceva has been used to treat more than
182,000 patients and has been approved in over 80 countries
worldwide.
Roche in Oncology
The Roche Group, including its members Genentech in the
United States and Chugai in Japan, is the world's leading
provider of cancer care products, including anti-cancer
treatments, supportive care products and diagnostics. Its
oncology business includes an unprecedented five products
proven to provide survival benefit in different major
tumour indications: Avastin, Herceptin, and Xeloda in
advanced-stage breast cancer, Herceptin in early-stage
HER2-positive breast cancer, MabThera in non-Hodgkin's
lymphoma, Avastin and Xeloda in colorectal cancer, Avastin
and Tarceva in non-small cell lung cancer and Tarceva in
pancreatic cancer (1).
In addition to these anti-cancer agents, the Roche
oncology portfolio includes a comprehensive collection of
medicines that can help improve the quality of life of
cancer patients: Bondronat (for prevention of skeletal
events in patients with breast cancer and bone metastases,
hypercalcaemia of malignancy), Kytril (for chemotherapy and
radiotherapy-induced nausea and vomiting), Neupogen (for
cancer-related neutropenia), and NeoRecormon (for anaemia
in various cancer settings). CERA is the most recent
demonstration of Roche's commitment to anaemia management.
Other oncology products include Furtulon (for colorectal
cancer) and Roferon-A (for hairy cell and chronic myeloid
leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell
carcinoma). The Roche Group's cancer medicines generated
sales of more than 7.7 billion Swiss francs in 2004.
In addition to the medicines, Roche is developing new
diagnostic tests that will have a significant impact on
disease management for cancer patients in the future. With
a broad portfolio of tumour markers for prostate,
colorectal, liver, ovarian, breast, stomach, pancreas and
lung cancer, as well as a range of molecular oncology
tests, Roche will continue to be the leader in providing
cancer-focused treatments and diagnostics.
The unmatched Roche oncology portfolio as well as an
extensive external innovation base through collaborations
with companies and academia is what makes it possible for
Roche to provide more effective cancer therapies.
In the United States, Herceptin, MabThera (Rituxan),
Avastin and Tarceva are marketed either by Genentech alone
or together with its partners Biogen Idec Inc. (MabThera)
and OSI (Tarceva). Outside of the United States, Roche and
its Japanese partner Chugai are responsible for the
marketing of these medicines.
About Roche
Headquartered in Basel, Switzerland, Roche is one of
the world's leading research-focused healthcare groups in
the fields of pharmaceuticals and diagnostics. As the
world's biggest biotech company and an innovator of
products and services for the early detection, prevention,
diagnosis and treatment of diseases, the Group contributes
on a broad range of fronts to improving people's health and
quality of life. Roche is the world leader in in-vitro
diagnostics and drugs for cancer and transplantation, a
market leader in virology and active in other major
therapeutic areas such as autoimmune diseases,
inflammation, metabolic disorders and diseases of the
central nervous system. In 2006 sales by the
Pharmaceuticals Division totalled 33.3 billion Swiss
francs, and the Diagnostics Division posted sales of 8.7
billion Swiss francs. Roche has R&D agreements and
strategic alliances with numerous partners, including
majority ownership interests in Genentech and Chugai, and
invests approximately 7 billion Swiss francs a year in
R&D. Worldwide, the Group employs about 75,000 people.
Additional information is available on the Internet at
http://www.roche.com .
Disclaimer: Cautionary statement regarding
forward-looking statements
This document contains certain forward-looking
statements. These forward-looking statements may be
identified by words such as 'believes', 'expects',
'anticipates', 'projects', 'intends', 'should', 'seeks',
'estimates', 'future' or similar expressions or by
discussion of, among other things, strategy, goals, plans
or intentions. Various factors may cause actual results to
differ materially in the future from those reflected in
forward-looking statements contained in this document,
among others: (1) pricing and product initiatives of
competitors; (2) legislative and regulatory developments
and economic conditions; (3) delay or inability in
obtaining regulatory approvals or bringing products to
market; (4) fluctuations in currency exchange rates and
general financial market conditions; (5) uncertainties in
the discovery, development or marketing of new products or
new uses of existing products, including without limitation
negative results of clinical trials or research projects,
unexpected side-effects of pipeline or marketed products;
(6) increased government pricing pressures; (7)
interruptions in production; (8) loss of or inability to
obtain adequate protection for intellectual property
rights; (9) litigation; (10) loss of key executives or
other employees; and (11) adverse publicity and news
coverage. The statement regarding earnings per share growth
is not a profit forecast and should not be interpreted to
mean that Roche's earnings or earnings per share for any
current or future period will necessarily match or exceed
the historical published earnings or earnings per share of
Roche.
End Notes:
-- IARC. GLOBOCAN 2002. Cancer incidence, Mortality and
Prevalence Worldwide.
-- F. Shepherd, J. Rodrigues Pereira, T. Ciuleanu. et
al. Erlotinib in Previously Treated Non-Small Cell Lung
Cancer, A Trial of the National Cancer Institute of Canada
Clinical Trials Group. N Engl J Med 2005;353:123-32.
For more information, please contact:
Lester B. Davis, International Communications Manager
Tarceva
Phone: +41-61-688-2078
Email: lester.davis@roche.com
Ann Blumenstock
Resolute Communications
Phone: +44-20-7357-8187
Email: ann.blumenstock@resolutecommunications.com
2007'09.08.Sat
Strong Global Support for Open XML as It Enters Final Phase of ISO Standards Process
September 04, 2007
Significant Participation by National Bodies in ISO/IEC
Ratification Process for Open XML; Final Decision Expected
in March 2008 at Close of Ballot Resolution Period.
REDMOND, Wash., Sept. 4 /Xinhua-PRNewswire/ -- Today
the International Organization for Standardization (ISO)
released the results of the preliminary ballot to
participating National Body members for the ISO/IEC DIS
29500 (Ecma 376 Office Open XML file formats) ratification
process. The results show that 51 ISO members, representing
74 percent of all qualified votes, stated their support for
ratification of Open XML. Along with their votes, the
National Bodies also provided invaluable technical comments
designed to improve the specification. Many of the remaining
ISO members stated that they will support Open XML after
their comments are addressed during the final phase of the
process, which is expected to close in March 2008.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO )
With at least 87 countries taking part in some way, the
Open XML review represents an unprecedented level of
participation in the standardization of a document format.
Fifty-one ISO members voicing support at this preliminary
stage of the process compares favorably with the 32 ISO
members supporting Open Document Format (ODF) 1.0 at the
end of its process and the 15 ISO members supporting
PDF/A-1 at the end of its process. This widespread
participation and support is consistent with the rapid
adoption of the Ecma Office Open XML file formats across
multiple platforms and products from a wide range of IT
vendors (including Apple, Novell, Corel, Sun, Microsoft,
Java developers and Linux distributors), creating real
value for IT users around the globe.
"We are extremely delighted to see that 51 ISO
members, representing 74 percent of the qualified votes,
have already voiced their support for ISO ratification of
Open XML, and that many others have indicated they will
support ratification once their comments are resolved in
the next phase of the ISO process," said Tom
Robertson, general manager for Interoperability and
Standards at Microsoft Corp. "This preliminary vote is
a milestone for the widespread adoption of the Open XML
formats around the world for the benefit of millions of
customers. Given how encouraging today's results were, we
believe that the final tally in early 2008 will result in
the ratification of Open XML as an ISO standard."
Technical Input Will Enhance the Standard
Today's results represent the beginning of the third
phase of the ISO/IEC process, called "ballot
resolution," during which time Ecma International will
respond to all comments that have been submitted by ISO
National Bodies and provide them with a final opportunity
to voice their support.
"Technical experts around the world have provided
invaluable feedback and technical recommendations for
evolving the format," Robertson said. "The high
quality of the Open XML format will be improved as a result
of this process, and we take seriously our role in working
within the Ecma technical committee to address the comments
received. We believe that the ISO National Bodies will
be pleased with the results."
The ISO/IEC process is also designed to create maximum
opportunities for ISO members to move from "no"
to "yes" in this final phase, and we fully expect
the total number of supporting votes to grow.
"The objective of the standardization process,
whether with Ecma International, ISO/IEC or another
standards body, is ultimately to refine a specification and
achieve a positive consensus around its formal adoption for
the benefit of the entire industry," said Hugo
Lueders, group director of EU Public Policy for the
Computer Industry Technology Association. "Given the
remarkable level of participation from the global standards
community, the results from this preliminary ballot are very
encouraging."
Although no date has been formally set, the final tally
is likely to take place in March 2008. ISO/IEC requires that
at least 75 percent of all "yes" or "no"
votes (qualified votes) and at least two-thirds of
"P" members that vote "yes" or
"no" support ratification of a format in the Fast
Track process. More information about the ISO/IEC JTC-1
process and its participants is available at
http://www.iso.org/iso/standards_development/processes_and_procedures/iso_iec_directives_and_iso_supplement.htm
(Due to length of URL, please cut and paste into browser.).
Widespread Support for Open XML
The Ecma Office Open XML file formats are being rapidly
adopted across multiple platforms and products from a wide
range of IT vendors, creating real value for IT users
around the globe. Thousands of companies from 67 countries
on six continents have raised their voices in support of
Open XML and its ratification by ISO/IEC at
http://www.openxmlcommunity.org. As well, the open standard
has also been gaining broad adoption across the software
industry for use on a variety of platforms - including
Linux, Windows(R), Mac OS and the Palm OS. Independent
software vendors (ISVs) and platform providers around the
world - such as Apple, Corel, Sun, Microsoft and Novell -
are developing solutions using Open XML. Many developers
working with the formats are active contributors to
http://www.openxmldeveloper.org.
Those working with Open XML can attest to the benefits
of this open file format in the areas of file and data
management, data recovery, interoperability with
line-of-business systems, and the long-term preservation of
documents. Open XML is optimized for the level of precision
and detail that facilitates carrying forward billions of
existing files. As well, Open XML file formats are uniquely
capable of integrating other types of systems and data with
Open XML documents, while maintaining a clean, simple
separation of presentation (Open XML markup) and data
(custom schemas and instances thereof). This means that
organizations can use Open XML formats to report
information from other applications and systems without
having to translate it first, which is a key innovation for
developers seeking to incorporate real-time business
information into their documents, or those who seek to
"tag" documents with their own categorization
system to improve their understanding of its contents.
More information about Open XML, as well as available
solutions using the open standard specification, is
available at
http://www.openxmlcommunity.org/momentum.aspx#technology .
Commitment to Interoperability
The Open XML Translator (
http://www.sourceforge.net/projects/odf-converter ) is one
among many interoperability projects Microsoft has
undertaken. We continue to work with customers and others
in the industry to address the critical interoperability
issues of our customers through the delivery of products
that are interoperable by design, collaboration on
interoperability projects, providing access to
interoperability technologies, and standardization. Other
evidence of collaboration includes our technical
collaborations with AOL LLC and Yahoo! Inc. for instant
messaging interoperability, the broad collaboration with
Novell on virtualization, document formats and intellectual
property, and the creation of the Interoperability Vendor
Alliance. More information is available at
http://www.microsoft.com/interop .
Founded in 1975, Microsoft (Nasdaq: MSFT) is the
worldwide leader in software, services and solutions that
help people and businesses realize their full potential.
NOTE TO EDITORS:
If you are interested in viewing additional information
on Microsoft, please visit the Microsoft(R) Web page at
http://www.microsoft.com/presspass on Microsoft's corporate
information pages. Web links, telephone numbers and titles
were correct at time of publication, but may since have
changed. For additional assistance, journalists and
analysts may contact Microsoft's Rapid Response Team or
other appropriate contacts listed at
http://www.microsoft.com/presspass/contactpr.mspx .
For more information, please contact:
Rapid Response Team
Waggener Edstrom Worldwide
Tel: +1-503-443-7070
Email: rrt@waggeneredstrom.com
2007'09.08.Sat
日清食品、中華カップめん「日清チキンラーメンどんぶり プラス野菜カレー」を発売
－味わい深い、野菜たっぷりのカレー味－
どんぶり型中華カップめん
「日清チキンラーメンどんぶり プラス野菜カレー」
新発売のご案内
日清食品株式会社（社長：安藤宏基）は、「日清チキンラーメンどんぶり」から、新しい味のバリエーションとして「日清チキンラーメンどんぶり プラス野菜カレー」を、８月２０日（月）より全国一斉に新発売いたします。
【開発の意図】
「日清チキンラーメンどんぶり」は、チキンラーメンのおいしさそのままに、カップめんで手軽に味わえる商品として、１９９０年の発売以来、ご好評をいただいております。弊社では、暑い夏に向けて食欲を刺激するカレー味の「日清チキンラーメンどんぶり プラス野菜カレー」を開発しました。当商品は、具材にたまねぎ、ニンジン、キャベツ、グリーンアスパラなど野菜をたっぷり入れ、スープはチキンラーメンの鶏ガラスープのうまみにカレーの風味が合わさり、すっきりとした中にもコクのある味わい深いカップめんに仕上げました。
弊社では８月２５日のチキンラーメンバースデーに向け、当商品を投入し「チキンラーメン」ブランド全体の活性化を図ります。
【商品コンセプト】
すっきりとしたなかにもコクのある味わい深い、野菜たっぷりの「カレー味」のチキンラーメンどんぶりです。
たっぷりと野菜が入り、夏場にぴったりのすっきりとしたカレー味になっています。
【商品特徴】
（１）め ん
おなじみのコシとつるみのあるチキンラーメンのめんです。
（２）スープ
鶏ガラのうまみにカレーの風味をプラスし、すっきりとした中にもコクのある味わい深い「カレー味」のチキンラーメンです。
（３）具 材
カレー味のブロック成型野菜（たまねぎ、ニンジン、キャベツ）とグリーンアスパラが、たっぷり入っています。
【商品概要】
※ 関連資料参照
● 関連リンク
2007'09.08.Sat
日清食品、ボックスヌードル「日清Ｃｈｉｎ」シリーズ３品の販売地域を全国に拡大
－新スタイルパッケージで自由に楽しい、ボックスヌードル－
「日清Ｃｈｉｎ」
全国地区へ販売チャネル拡大と新発売のご案内
１．「日清Ｃｈｉｎ ソース焼そば」
２．「日清Ｃｈｉｎ 五目焼そば」
３．「日清Ｃｈｉｎ スパゲッティ"ボロネーゼ"」
４．「日清Ｃｈｉｎ 上海焼そば」（新発売）
５．「日清Ｃｈｉｎ アラビアータ」（新発売）
日清食品株式会社（社長：安藤宏基）は、８月２０日（月）より、「自由なスタイルで食べられる本格派のカップ焼そば」をテーマにした、楽しさとおいしさが共存する新スタイルパッケージのボックスヌードル「日清Ｃｈｉｎ」シリーズ３品（「ソース焼そば」「五目焼そば」「スパゲッティ"ボロネーゼ"」）の発売地区を全国に拡大、また量販店等全業態へ販売チャネルも拡大します。さらに、ラインナップ強化のため、「日清Ｃｈｉｎ 上海焼そば」「日清Ｃｈｉｎ アラビアータ」の２品を追加新発売します。
◆商品コンセプト
お湯の要らないレンジ調理のＢｏｘ型カップ焼そば。
自由なスタイルで楽しくおいしい。それがＣｈｉｎスタイル！
◆全国展開および新フレーバー発売の意図
本年５月に関東甲信越地区のコンビニエンスストア限定で先行発売した「日清Ｃｈｉｎ」シリーズは、本格的な食感、斬新なパッケージ、新しい食スタイル、そして豊かな話題性が２０代～３０代男女を中心に好評を頂き、カップめんの電子レンジ調理時代を切り開きました。今回、発売地区を全国に拡大するとともに、量販店等全業態へ販売チャネルも拡大します。さらに、新フレーバーとして従来では表現が難しかった、微妙な味わいにチャレンジした「上海焼そば」と、サルサ風のアクセントを効かせた「アラビアータ」の２品を追加し、ラインナップを充実させて、電子レンジ調理カップめん市場の拡大を目指します。
◆「日清Ｃｈｉｎ」とは
少子高齢化、個食化、グルメ化など食を取り巻く環境は大きく変化しています。そこで弊社では、より簡便性を追求し、より本格的なおいしさへのこだわり、さらによりファッション性と楽しさを意識したカップめんの提案として、アメリカの中華のテイクアウトからヒントを得て、日本流にアレンジしたボックスヌードル「日清Ｃｈｉｎ」を開発しました。生タイプめんでしか味わえないしっかりとした食感、お水もお湯も要らない電子レンジでチンするだけの簡単調理に、ハリウッド映画を連想させる持ちやすくおしゃれなＴａｋｅ Ｏｕｔ Ｓｔｙｌｅが特徴です。おいしさに楽しさとファッション性が加わった、今までとは違うワクワクする新商品です。Ｂｏｘの中では、弊社が誇る最新の生タイプめんの技術と、香り立つソース、充実の具材がアツアツのおいしさを奏でます。家でオフィスで、夜食にランチに、仲間と一緒に、Ｂｏｘ型ならではの自由なスタイルでお楽しみいただけます。
◆商品特徴
（※ 関連資料を参照してください。）
◆商品概要
（※ 関連資料を参照してください。）
（※ 商品画像、商品特徴、商品概要は関連資料を参照してください。）
2007'09.08.Sat
キーコーヒー、プレミアム簡易抽出型コーヒー新型「ＤＲＩＰ ＯＮ（ドリップオン）」を発売
新提案：“３度の香り”が楽しめるプレミアム簡易抽出型レギュラーコーヒー
新型『ＤＲＩＰ ＯＮ』（ドリップオン）新発売！
＝直木賞作家石田衣良氏等、８名による書き下ろし連載小説掲載、９月１４日より専用ＷＥＢサイトもオープン！＝
＜２００７年９月１日（土）発売＞
キーコーヒー株式会社（本社：東京都港区、社長：柴田裕、資本金：４４億６５００万円）では、１９９７年発売の『ＤＲＩＰ ＯＮ』（ドリップオン）を、“３度の香り”が楽しめるプレミアム簡易抽出型コーヒーとして、２００７年９月１日（土）より、新型『ドリップオン』全１２アイテムを全国発売いたします。
『ドリップオン』をはじめとした、お湯を注ぐだけで簡単にレギュラーコーヒーが楽しめるタイプのコーヒーは「簡易抽出型」と言われ、コーヒーメーカー各社がラインアップ、家庭用レギュラーコーヒー市場の中で、年々、順調に売上が伸長しているカテゴリーです。
新型「ドリップオン」は、お客様がコーヒー飲用に求める最大のニーズである「香り」に注目。理想の香りをお届けするため、弊社が培った様々なコーヒー製造の技術を駆使、素材から機能にいたるまで全てリニューアルし、プレミアムドリップコーヒーとして新発売します。
また、９月１４日（金）より、弊社ホームページ内に『ＤＲＩＰ ＯＮスペシャルサイト書茶～しょさ～』（http://www.keycoffee.co.jp/dripon/index.html）を開設。直木賞作家の石田衣良氏をはじめ、合計８名の人気作家が‘香りと記憶’をテーマに、各自１ヶ月、前・中・後篇の３話完結で、オリジナルの書き下ろし小説連載を展開します。
【新型『ドリップオン』の特徴】
※添付資料を参照
新型『ドリップオン』製品概要
※添付資料を参照
＊お客様問合せ先：０１２０－１９２００８（お客様センター）
『ＤＲＩＰ ＯＮスペシャルサイト書茶～しょさ～』概要
◆展開期間：
２００７年９月１４日（金）～２００８年６月予定
◆サイトＵＲＬ：
http://www.keycoffee.co.jp/dripon/index.html
◆内容：
“香りと記憶”をテーマに、人気作家８名が、各自、前・中・後篇の３話完結、『ＤＲＩＰ ＯＮスペシャルサイト書茶～しょさ～』オリジナルの書き下ろし連載小説を執筆。
【参加予定作家】
石田衣良、朱川湊人、熊谷達也、角田光代、小池真理子、阿川佐和子、他２名
広告
ブログ内検索
アーカイブ
カウンター